In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Product Liability: When Bad Things Happen to Good Companies

Executive Summary

Guidant's problems with its ICD business, coming in the midst of its merger negotiations with Johnson & Johnson, highlighted the impact that product recalls and problems can have for companies. Generally speaking, product liability is becoming a bigger issue for medical device companies as consumers grow more skeptical that the government is protecting their interests where product safety is concerned.

You may also be interested in...



CMS News is Good for Troubled Markets

There was probably no group more relieved than the makers of implantable cardioverter defibrillators (ICDs) to see the Centers for Medicaid and Medicare Services (CMS) in August drastically modify its proposal to slash hospital reimbursement. The change is as a result of effective lobbying from the medical device community as well as the hospital industry, and is welcome news to all high-end device makers.

‘Buy American’ Executive Order Receives Backlash

To build a “reliable long-term domestic production” of medicines and related supplies and to “minimize potential shortages,” US President Donald Trump has signed a ‘Buy American’ executive order. However, the move has left industry wondering if it is a sustainable solution.

Bayer Back In M&A Mode To Boost Pipeline

The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel